Evidence map›Paper›PMID 39919111›Full record

ArticlePloS one2025

Direct detection and identification of viruses in saliva using a SpecID ionization modified mass spectrometer.

Pierre Alusta, Angel Paredes, Marli Azevedo, Lisa Mullis, Dan Buzatu

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pierre AlustaSystems Biology Division, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, AR, United States of America.ORCID 0000-0001-8325-9955
Angel ParedesNCTR / ORA Nanotechnology Facility, Office of Scientific Coordination, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, AR, United States of America.
Marli AzevedoDivision of Microbiology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, AR, United States of America.ORCID 0000-0002-8591-7269
Lisa MullisDivision of Microbiology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, AR, United States of America.
Dan BuzatuSystems Biology Division, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, AR, United States of America.ORCID 0000-0002-4904-7577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 (SARS-CoV-2) pandemic has led to a significant mortality globally and persistent health challenges in many survivors. Early accurate diagnosis, surveillance, identification of cohorts, and prophylaxis are considered essential measures to reduce the spread of infectious viral pathogens such as SARS-CoV-2. A reliable, fast, high-throughput screening method that can detect viral particles and identify the pathogenic virus in infected individuals could help to reduce the spread of the next viral threat through quick knowledge and implementation of appropriate prevention strategies. Since respiratory viruses are typically present in nasal and oral secretions, saliva is a good target for testing for viral infections. Saliva testing has slowly gained popularity in the diagnostics based on biomarkers and other constituents ranging from organic compounds (e.g., food additives), peptides, and even microorganisms. Polymerase chain reaction (PCR) remains the gold standard for sensitive detection of SARS-CoV-2 infection in biological samples. However, while PCR testing for COVID is sensitive and widely used by hospitals, the method has a false-negative rate of 15-20% and is kit-based necessitating the development of alternative methods of detection that provide higher accuracy. This paper describes the use of a SpecID Mass Spectrometer that can detect the presence of viral particles in saliva at very low levels (<500 virions/0.5 ml). The main goal of this study was to demonstrate that our previously developed, portable, mass spectrometry based method, SpecID, could also be sued for detecting viruses in saliva, including but not limited to SARS-CoV-2; the SpecID method has the potential to provide a reliable solution that overcomes some of the challenges with molecular testing like PCR.

Indexed as

COVID-19Mass SpectrometrySalivaSARS-CoV-2Humans

Identifiers

PMID39919111
PMCPMC11805448

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.